The distribution of Next Generation Immunology Drug Market Share is currently a highly contested area, marked by the gradual erosion of dominance held by the first-generation TNF-alpha inhibitors. While these legacy biologics still command a significant portion of the patient volume, their revenue share is increasingly pressured by the entry of numerous biosimilars and the launch of new, mechanistically different biologics targeting IL-17, IL-23, and IL-6 pathways. The key competitive battleground for market share is now the second-line and third-line treatment settings, where clinicians select between established but less specific treatments, and newer, more targeted agents that promise higher efficacy for specific patient subsets.